The US Food and Drug Administration (FDA) has approved an investigational new drug application from Vegenics, a subsidiary of Circadian Technologies, to commence clinical trials of VGX-100 for the treatment cancer patients with solid tumours.

VGX-100 is a human antibody that acts against the human VEGF-C protein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In animal models, VGX-100 combined with Avastin and chemotherapy has been shown to reduce tumour growth and tumour spread, and improve tumour inhibition.

The Phase I study will investigate VGX-100 in patients with a variety of late-stage cancers.

Circadian Technologies CEO Robert Klupacs said the company expects to start clinical trials before the end of 2011, with results becoming available in the second half of 2012.

The company is also developing VGX-100 for other cancer indications, as well as an agent to treat front-of the-eye diseases.